Study Summary
This is a Phase 1 study to evaluate FIT-CD19-CAR-T (ARM011) safety and tolerability, anti-tumor activity, cellular kinetics, immunogenicity, and exploratory biomarkers.
Want to learn more about this trial?
Request More InfoInterventions
ARM011BIOLOGICAL
ARM011 is an autologous, CD19 targeted CAR T-cell product developed on fast-in-time (FIT) platform-a non-viral, 2-day rapid manufacturing process
FludarabineDRUG
Administered prior to infusion of ARM011
CyclophosphamideDRUG
Administered prior to infusion of ARM011
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| National Taiwan University Hospital | Taipei | Taiwan |